Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.39 |
| ▸ | EIF4A3 | P38919 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168342 | 1.00 | ACHE (0.40) | ACHEMDM2EIF4A3MEN1KMT2A | |
| SCHEMBL4154819 | 0.85 | CNR1 (0.48) | ACHEMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4160818 | 0.81 | RIPK1 (0.44) | ACHEMDM2EIF4A3MEN1KMT2A | |
| SCHEMBL4160826 | 0.81 | RIPK1 (0.44) | ACHEMDM2EIF4A3MEN1KMT2A | |
| SCHEMBL13699635 | 0.80 | MEN1 (0.41) | ACHEMDM2EIF4A3MEN1KMT2A | |
| SCHEMBL4168346 | 0.78 | NR1H2 (0.48) | ACHEEIF4A3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11958336 | 0.74 | CNR1 (0.47) | MDM2EIF4A3 | |
| SCHEMBL19690344 | 0.73 | CNR1 (0.45) | MDM2MEN1KMT2ARXFP1 | |
| SCHEMBL4177222 | 0.72 | CNR1 (0.47) | MDM2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL38661618 | 0.72 | MEN1 (0.46) | MDM2MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1960391-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | Vernalis (R&D) Limited (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007057687-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | VERNALIS (R & D) LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | ACHE 3470/4885MDM2 2997/4885EIF4A3 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.